212127-81-6

Basic information

• Product Name: 3,6-dihydropyran-5-boronic ester
• Synonyms: 3,6-dihydropyran-5-boronic ester;2-(5,6-Dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;(5,6-DIHYDRO-2H-PYRAN-3-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 212127-81-6
• Molecular Formula: C₁₁H₁₉BO₃
• Molecular Weight: 210.08
• Product Categories: Organic boronic acid
• Mol File: 212127-81-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 238.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.01±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 3,6-dihydropyran-5-boronic ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dihydropyran-5-boronic ester(212127-81-6)
• EPA Substance Registry System: 3,6-dihydropyran-5-boronic ester(212127-81-6)

Safety Data

• Hazardous Substances Data: 212127-81-6(Hazardous Substances Data)

Usage

General Description

3,6-dihydropyran-5-boronic ester is a chemical compound that belongs to the boronic ester family. It is a colorless, flammable liquid that is insoluble in water but soluble in organic solvents. 3,6-dihydropyran-5-boronic ester is commonly used in organic synthesis as a building block for the creation of various pharmaceuticals, agrochemicals, and materials. Its boronic ester group makes it a versatile reagent for Suzuki-Miyaura cross-coupling reactions, allowing for the formation of carbon-carbon bonds. Additionally, it has potential applications in the development of new drug candidates and as a ligand in transition metal catalysis. 3,6-dihydropyran-5-boronic ester is typically handled and stored under inert atmosphere due to its sensitivity to air and moisture.

Upstream product

• 93199-28-1 4-(prop-2-yn-1-yloxy)but-1-ene 
• 23462-75-1 5,6-dihydro-2H-pyran-3(4H)-one 
• 73183-34-3 bis(pinacol)diborane 
• 1227068-80-5 5,6-dihydro-2H-pyran-3-yl trifluoromethanesulfonate 
• 212127-72-5 2-[3-(but-3-en-1-yloxy)prop-1-en-2-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Relevant articles and documents

Multigram Synthesis of Heterabicyclo[n.1.0]alkan-1-yl Trifluoroborates

An approach to the synthesis of oxa- and azabicyclo[n.1.0]alkan-1-yl trifluoroborates on a multigram scale was developed. Two synthetic strategies were evaluated: the first based on the lithiation–borylation of the corresponding 2-bromoallyl derivatives, and the other relying on regioselective hydroboration of the appropriate hetera-substituted enynes. The second method appeared to be more efficient in terms of scalability and substrate scope. Further steps included ring closing-metathesis, mild palladium-catalyzed cyclopropanation with diazomethane, and reaction with KHF2 and furnished the title compounds in up to 50 g scale in a single run (10–41 % overall yield, 4–5 steps).

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.